Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma.

Mednet Member

Medical Oncology · Columbia University Medical Center

A subset of patients with MCL have a significantly longer survival (often more than 7-10 years) and a more indolent disease course. Two separate groups have reported patients who did not receive up-front chemotherapy at the time of diagnosis but were instead actively monitored, the watch-a...